Think of Enterprise Value as the theoretical takeover price. It is more comprehensive than market capitalization (Market Cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.
EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Novartis India's Enterprise Value is ₹30,159 Mil.
Novartis India's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 was ₹1,309 Mil. Therefore, Novartis India's EV-to-EBIT ratio for today is 23.04.
EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA. As of today, Novartis India's Enterprise Value is ₹30,159 Mil.
Novartis India's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 was ₹1,329 Mil. Therefore, Novartis India's EV-to-EBITDA ratio for today is 22.70.
EV-to-Revenue is calculated as Enterprise Value divided by its Revenue. As of today, Novartis India's Enterprise Value is ₹30,159 Mil.
Novartis India's Revenue for the trailing twelve months (TTM) ended in Mar. 2026 was ₹3,543 Mil. Therefore, Novartis India's EV-to-Revenue ratio for today is 8.51.
EV-to-FCF is calculated as Enterprise Value divided by its Free Cash Flow. As of today, Novartis India's Enterprise Value is ₹30,159 Mil.
Novartis India's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 was ₹0 Mil. Therefore, Novartis India's EV-to-FCF ratio for today is .
*** Please note that the current Enterprise Value is calculated using the current market capitalization and the most recently available financial data. If key financial fields—Long-Term Debt & Capital Lease Obligation and Short-Term Debt & Capital Lease Obligation—are recorded as null in the latest reporting period, our data vendor will default to using data from the prior period with valid entries.
Novartis India (BOM:500672) Enterprise Value Explanation
When an investor buy a company, the investor needs to pay not only the common shares, he/she also needs to pay the shareholders of Preferred Stocks. He also assumes the debt of the company, and receives the cash on the company's balance sheet.
If a company has more cash than debt, the investor actually pays less than the Market Cap because he immediately owns the cash once the transaction goes through.
The market value of Preferred Stock needs to be added to the market value of common stocks in the calculation of Enterprise Value.
For the companies with the same Market Cap, the smaller the Enterprise Value is, the cheaper the company is.
Enterprise Value can be negative when the company's net cash is more than its Market Cap. In this case the investor is basically getting the company for free and get paid for that.
1. EV-to-EBIT is calculated as Enterprise Value divided by its EBIT.
Novartis India's current Enterprise Value is ₹30,159 Mil.
Novartis India's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹1,309 Mil.
2. EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA.
Novartis India's current Enterprise Value is ₹30,159 Mil.
Novartis India's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹1,329 Mil.
Novartis India's current Enterprise Value is ₹30,159 Mil.
Novartis India's Revenue for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹3,543 Mil.
Novartis India's current Enterprise Value is ₹30,159 Mil.
Novartis India's Cash Flow from Operations for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹0 Mil.
Novartis India's current Enterprise Value is ₹30,159 Mil.
Novartis India's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹0 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Novartis India Enterprise Value Related Terms
Novartis India Enterprise Value Historical Data
* Premium members only.
The historical data trend for Novartis India's Enterprise Value can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BOM:500672 vs ZTS, UTHR: Enterprise Value Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Novartis India's Enterprise Value, along with its competitors' market caps and Enterprise Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Novartis India Enterprise Value vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Novartis India's Enterprise Value distribution charts can be found below:
* The bar in red indicates where Novartis India's Enterprise Value falls into.
Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.
Novartis India's Enterprise Value for the fiscal year that ended in Mar. 2026 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Novartis India (BOM:500672) has a Enterprise Value of ₹30,159 Mil as of Jul. 12, 2026. Enterprise value equals the sum of market cap, debt and preferred shares less cash and equivalents. View historical data on Novartis India and its competitors.
Is Novartis India's Enterprise Value too high?
Novartis India's current Enterprise Value is ₹30,159 Mil. Overall, Novartis India has a GF Score™ of 65/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Novartis India's Enterprise Value compare to ZTS and UTHR?
Novartis India's Enterprise Value of ₹30,159 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Enterprise Value for a Drug Manufacturers company?
A good Enterprise Value depends on the Drug Manufacturers industry context. However, Enterprise Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Enterprise Value mean?
A high Enterprise Value can signal that a stock is expensive relative to its fundamentals. Enterprise value equals the sum of market cap, debt and preferred shares less cash and equivalents. View historical data on Novartis India and its competitors. Novartis India's current Enterprise Value is ₹30,159 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Novartis India stock overvalued right now?
Based on GuruFocus' analysis, Novartis India (BOM:500672) is currently considered Significantly Overvalued. The stock's GF Value™ is ₹927.67, compared to a current price of ₹1,490.85 — trading 60.7% above its estimated fair value. The current Enterprise Value is ₹30,159 Mil. Novartis India's overall GF Score™ is 65/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Enterprise Value calculated?
Enterprise Value is calculated from a company's financial statements. For Novartis India (BOM:500672), the current Enterprise Value is ₹30,159 Mil as of Jul. 12, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Novartis India (BOM:500672) Overvalued in 2026?
Based on GuruFocus' analysis, Novartis India stock appears to be overvalued.
The current stock price of ₹1,490.85 is trading 60.7% above its estimated GF Value™ of ₹927.67.
GuruFocus considers Novartis India to be Significantly Overvalued.
Key valuation signals for BOM:500672:
Enterprise Value: ₹30,159 Mil
GF Value™: ₹927.67 vs. price of ₹1,490.85 (60.7% above fair value)
No single metric tells the full story. See the BOM:500672 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Novartis India Ltd is an Indian-based pharmaceutical company. The company is engaged in the trading of Drugs and Pharmaceuticals. It derives revenue from operations in India. The company operates in a single business segment, namely Pharmaceutical Business. Its Pharmaceutical business focuses on Bone and Pain, Transplantation Immunology, and Neurosciences.
65GF Score
Get the complete analysis for BOM:500672
Enterprise Value is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:500672 has been successfully added to your 
